Home Onyx Snubbing Amgen Paves Way for 89% Premium: Real M&A
 

Keywords :   


Onyx Snubbing Amgen Paves Way for 89% Premium: Real M&A

2013-07-03 06:25:34| Biotech - Topix.net

Onyx Pharmaceuticals Inc. , which surged more than 50 percent after rejecting a bid from Amgen Inc., is betting that potential suitors from Bayer AG to Bristol-Myers Squibb Co.

Tags: real ma premium onyx

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news

»
07.07Tropical Storm Beryl Public Advisory Number 36A
07.07Summary for Tropical Storm Beryl (AT2/AL022024)
07.07Atlantic Tropical Weather Outlook
07.07Eastern North Pacific Tropical Weather Outlook
07.07Tropical Storm Beryl Potential Storm Surge Flooding Map
07.07Tropical Storm Beryl Probabilistic Storm Surge Graphics
07.07Tropical Storm Beryl Storm Surge Watch/Warning Map
07.07Tropical Storm Beryl Graphics
More »